FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washingto	n D C	20549
vvasiiiiiulu	II, D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GILEAD SCIENCES, INC.					2. Issuer Name and Ticker or Trading Symbol ASSEMBLY BIOSCIENCES, INC. [ASMB]									ationship of k all applica Director	ble)	Perso] 10% Ow	ner		
(Last)	(F	First)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/17/2024									Officer (g	give title		Other (s below)	pecify	
333 LAKESIDE DRIVE					4. I1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Ind	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)															Form filed by One Reporting Person					
FOSTER	CITY C	A	94404											Form filed by More than One Reporting Person				ing		
(City)	(\$	State)	(Zip)		Rı	Rule 10b5-1(c) Transaction Indication														
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to sat the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										satisfy									
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Trans Date (Month/			/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.			4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			5. Amount Securities Beneficial Owned Fo	For		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				,iii3ti. 4)			
Common Stock 06/3				06/1	7/2024				P	P		179,500 A		1,268,972		D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	Execution Da		nsaction de (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisabl Expiration Date (Month/Day/Year)		le and 7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)		ies g Security	Derivative Security curity (Instr. 5)		er of e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Co	de V	v	(A)	(D)	Date Exer	e rcisable	Ex _I	piration te	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	ion(s)			
Warrant to purchase Common Stock	\$17	06/17/2024		F			179,500			(2)	06/	18/2029 ⁽²⁾	Common Stock	179,500	(1)	179,5	00	D		

Explanation of Responses:

1. Pursuant to a securities purchase agreement between the Issuer and the Reporting Person, the Issuer issued and sold to the Reporting Person in a private placement 179,500 shares of the Issuer's common stock, par value \$0.001 per share ("Common Stock"), and a warrant to purchase 179,500 shares of Common Stock (the "Warrant") at a combined price of \$15.46 per share of Common Stock and accompanying warrant.

Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson

06/20/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} The Warrant is exercisable at any time after the date of issuance and expires on June 18, 2029. A holder of the Warrant may not exercise the Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.